Variant of TREM2 associated with the risk of Alzheimer's disease

New England Journal of Medicine

Volumn 368, Issue 2, 2013, Pages 107-116

  Jonsson, Thorlakur ^a   Stefansson, Hreinn ^a   Steinberg, Stacy ^a   Jonsdottir, Ingileif ^a,b   Jonsson, Palmi V ^b,c   Snaedal, Jon ^c   Bjornsson, Sigurbjorn ^c   Huttenlocher, Johanna ^d   Levey, Allan I ^g   Lah, James J ^g   Rujescu, Dan ^e   Hampel, Harald ^f   Giegling, Ina ^e   Andreassen, Ole A ^h,i   Engedal, Knut ^h,i   Ulstein, Ingun ^h   Djurovic, Srdjan ^h,i   Ibrahim Verbaas, Carla ^j   Hofman, Albert ^j   Ikram, M Arfan ^j   Van Duijn, Cornelia M ^j   Thorsteinsdottir, Unnur ^a,b   Kong, Augustine ^a   Stefansson, Kari ^a,b   more..

^a UNIVERSITY OF ICELAND   (Iceland)

^b UNIVERSITY OF ICELAND   (Iceland)

^c LANDSPITALI UNIVERSITY HOSPITAL   (Iceland)

^d UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^e MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^f GOETHE UNIVERSITY   (Germany)

^g EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h OSLO UNIVERSITY HOSPITAL   (Norway)

ⁱ UNIVERSITY OF OSLO   (Norway)

^j ERASMUS MEDICAL CENTER   (Netherlands)

more..

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E4; MEMBRANE RECEPTOR; TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2; UNCLASSIFIED DRUG;

ADULT; AGED; ALLELE; ALZHEIMER DISEASE; AMINO ACID SUBSTITUTION; APOE EPSILON 4 GENE; ARTICLE; COGNITION; CONTROLLED STUDY; GENE; GENE FREQUENCY; GENE FUNCTION; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC CODE; GENETIC RISK; GENETIC VARIABILITY; HETEROZYGOTE; HOMOZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MISSENSE MUTATION; NEUROPATHOLOGY; PRIORITY JOURNAL; PROTEIN FUNCTION; SINGLE NUCLEOTIDE POLYMORPHISM; TREM2 GENE;

EID: 84872088087     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1211103     Document Type: Article

References (50)

1. Castellani RJ, Rolston RK, Smith MA. Alzheimer disease. Dis Mon 2010;56:484-546.
2. Qiu C, Kivipelto M, von Strauss E. Epidemiology of Alzheimer's disease: occurrence, determinants, and strategies toward intervention. Dialogues Clin Neurosci 2009;11:111-28.
3. Cruts M, Theuns J, Van Broeckhoven C. Locus-specific mutation databases for neurodegenerative brain diseases. Hum Mutat 2012;33:1340-4.
4. Bertram L, Lill CM, Tanzi RE. The genetics of Alzheimer disease: back to the future. Neuron 2010;68:270-81.
5. Saunders AM, Strittmatter WJ, Schmechel D, et al. Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease. Neurology 1993;43:1467-72.
6. Strittmatter WJ, Saunders AM, Schmechel D, et al. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci U S A 1993;90:1977-81.
7. Holm H, Gudbjartsson DF, Sulem P, et al. A rare variant in MYH6 is associated with high risk of sick sinus syndrome. Nat Genet 2011;43:316-20.
8. Sulem P, Gudbjartsson DF, Walters GB, et al. Identification of low-frequency variants associated with gout and serum uric acid levels. Nat Genet 2011;43:1127-30.
9. Stacey SN, Sulem P, Jonasdottir A, et al. A germline variant in the TP53 polyadenylation signal confers cancer susceptibility. Nat Genet 2011;43:1098-103.
10. Rafnar T, Gudbjartsson DF, Sulem P, et al. Mutations in BRIP1 confer high risk of ovarian cancer. Nat Genet 2011;43:1104-7.
11. Jonsson T, Atwal JK, Steinberg S, et al. A mutation in APP protects against Alzheimer's disease and age-related cognitive decline. Nature 2012;488:96-9.
12. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-44.
13. Morris JN, Hawes C, Fries BE, et al. Designing the national resident assessment instrument for nursing homes. Gerontologist 1990;30:293-307.
14. Morris JN, Fries BE, Steel K, et al. Comprehensive clinical assessment in community setting: applicability of the MDSHC. J Am Geriatr Soc 1997;45:1017-24.
15. Morris JN, Fries BE, Mehr DR, et al. MDS Cognitive Performance Scale. J Gerontol 1994;49:M174-M182.
16. Brækhus A, Ulstein I, Wyller TB, Engedal K. The Memory Clinic - outpatient assessment when dementia is suspected. Tidsskr Nor Laegeforen 2011;131:2254-7.
17. Athanasiu L, Mattingsdal M, Kahler AK, et al. Gene variants associated with schizophrenia in a Norwegian genome-wide study are replicated in a large European cohort. J Psychiatr Res 2010;44:748-53.
18. Hofman A, Breteler MM, van Duijn CM, et al. The Rotterdam Study: objectives and design update. Eur J Epidemiol 2007;22:819-29.
19. Hofman A, van Duijn CM, Franco OH, et al. The Rotterdam Study: 2012 objectives and design update. Eur J Epidemiol 2011;26:657-86.
20. Kutyavin IV, Milesi D, Belousov Y, et al. A novel endonuclease IV post-PCR genotyping system. Nucleic Acids Res 2006;34(19):e128.
21. Eikelenboom P, Stam FC. Immunoglobulins and complement factors in senile plaques: an immunoperoxidase study. Acta Neuropathol 1982;57:239-42.
22. Ishii T, Haga S. Immuno-electron-microscopic localization of complements in amyloid fibrils of senile plaques. Acta Neuropathol 1984;63:296-300.
23. Akiyama H, Barger S, Barnum S, et al. Inflammation and Alzheimer's disease. Neurobiol Aging 2000;21:383-421.
24. Griffin WS, Stanley LC, Ling C, et al. Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease. Proc Natl Acad Sci U S A 1989;86:7611-5.
25. Rogers J, Luber-Narod J, Styren SD, Civin WH. Expression of immune system-associated antigens by cells of the human central nervous system: relationship to the pathology of Alzheimer's disease. Neurobiol Aging 1988;9:339-49.
26. Rozemuller JM, Eikelenboom P, Stam FC. Role of microglia in plaque formation in senile dementia of the Alzheimer type: an immunohistochemical study. Virchows Arch B Cell Pathol Incl Mol Pathol 1986;51:247-54.
27. Eikelenboom P, van Exel E, Hoozemans JJ, Veerhuis R, Rozemuller AJ, van Gool WA. Neuroinflammation - an early event in both the history and pathogenesis of Alzheimer's disease. Neurodegener Dis 2010;7:38-41.
28. Blalock EM, Chen KC, Stromberg AJ, et al. Harnessing the power of gene microarrays for the study of brain aging and Alzheimer's disease: statistical reliability and functional correlation. Ageing Res Rev 2005;4:481-512.
29. Lambert JC, Heath S, Even G, et al. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat Genet 2009;41:1094-9.
30. Hollingworth P, Harold D, Sims R, et al. Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat Genet 2011;43:429-35.
31. Bertram L, Lange C, Mullin K, et al. Genome-wide association analysis reveals putative Alzheimer's disease susceptibility loci in addition to APOE. Am J Hum Genet 2008;83:623-32.
32. Bouchon A, Dietrich J, Colonna M. Cutting edge: inflammatory responses can be triggered by TREM-1, a novel receptor expressed on neutrophils and monocytes. J Immunol 2000;164:4991-5.
33. Colonna M. TREMs in the immune system and beyond. Nat Rev Immunol 2003;3:445-53.
34. Bouchon A, Hernández-Munain C, Cella M, Colonna MA. DAP12-mediated pathway regulates expression of CC chemokine receptor 7 and maturation of human dendritic cells. J Exp Med 2001;194:1111-22.
35. Stefano L, Racchetti G, Bianco F, et al. The surface-exposed chaperone, Hsp60, is an agonist of the microglial TREM2 receptor. J Neurochem 2009;110:284-94.
36. Ito H, Hamerman JA. TREM-2, triggering receptor expressed on myeloid cell-2, negatively regulates TLR responses in dendritic cells. Eur J Immunol 2012;42:176-85.
37. Sessa G, Podini P, Mariani M, et al. Distribution and signaling of TREM2/DAP12, the receptor system mutated in human polycystic lipomembraneous osteodysplasia with sclerosing leukoencephalopathy dementia. Eur J Neurosci 2004;20:2617-28.
38. Carson MJ, Doose JM, Melchior B, Schmid CD, Ploix CC. CNS immune privilege: hiding in plain sight. Immunol Rev 2006;213:48-65.
39. Melchior B, Garcia AE, Hsiung BK, et al. Dual induction of TREM2 and tolerance-related transcript, Tmem176b, in amyloid transgenic mice: implications for vaccine-based therapies for Alzheimer's disease. ASN Neuro 2010;2(3):e00037.
40. Takahashi K, Rochford CD, Neumann H. Clearance of apoptotic neurons without inflammation by microglial triggering receptor expressed on myeloid cells-2. J Exp Med 2005;201:647-57.
41. Hamerman JA, Jarjoura JR, Humphrey MB, Nakamura MC, Seaman WE, Lanier LL. Cutting edge: inhibition of TLR and FcR responses in macrophages by triggering receptor expressed on myeloid cells (TREM)-2 and DAP12. J Immunol 2006;177:2051-5.
42. Hakola HP. Neuropsychiatric and genetic aspects of a new hereditary disease characterized by progressive dementia and lipomembranous polycystic osteodysplasia. Acta Psychiatr Scand Suppl 1972;232:1-173.
43. Madry H, Prudlo J, Grgic A, Freyschmidt J. Nasu-Hakola disease (PLOSL): report of five cases and review of the literature. Clin Orthop Relat Res 2007;454:262-9.
44. Nasu T, Tsukahara Y, Terayama K. A lipid metabolic disease - "membranous lipodystrophy" - an autopsy case demonstrating numerous peculiar membranestructures composed of compound lipid in bone and bone marrow and various adipose tissues. Acta Pathol Jpn 1973;23:539-58.
45. Paloneva J, Kestilä M, Wu J, et al. Loss-of-function mutations in TYROBP (DAP12) result in a presenile dementia with bone cysts. Nat Genet 2000;25:357-61.
46. Paloneva J, Manninen T, Christman G, et al. Mutations in two genes encoding different subunits of a receptor signaling complex result in an identical disease phenotype. Am J Hum Genet 2002;71:656-62. [Erratum, Am J Hum Genet 2003;72:225.]
47. Chouery E, Delague V, Bergougnoux A, Koussa S, Serre JL, Mégarbané A. Mutations in TREM2 lead to pure early-onset dementia without bone cysts. Hum Mutat 2008;29(9):E194-E204.
48. Guerreiro RJ, Lohmann E, Brás JM, et al. Using exome sequencing to reveal mutations in TREM2 presenting as a frontotemporal dementia-like syndrome without bone involvement. Arch Neurol 2012 October 8 (Epub ahead of print).
49. Montalbetti L, Ratti MT, Greco B, Aprile C, Moglia A, Soragna D. Neuropsychological tests and functional nuclear neuroimaging provide evidence of subclinical impairment in Nasu-Hakola disease heterozygotes. Funct Neurol 2005;20:71-5.
50. Wunderlich P. γ-Secretase mediated proteolytic processing of the triggering receptor expressed on myeloid cells-2 - functional implications for intracellular signalling. Bonn, Germany: University of Bonn, 2010.